AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this study, ampelopsin effectively downregulated the AKT and NF-κB signaling, but not ERK1/2, in HL60 AML and K562 CML cells, suggesting that the inhibitory effect of ampelopsin on leukemia cell growth may be involved in the blockade of AKT and NF-κB signaling pathways.